How should pregnancy‑induced hypertension be managed, including first‑line oral antihypertensive agents and indications for intravenous therapy?

Management of Pregnancy-Induced Hypertension

For oral antihypertensive therapy in pregnancy-induced hypertension, use extended-release nifedipine as first-line treatment, with labetalol as an alternative; for hypertensive emergencies (BP ≥160/110 mmHg lasting >15 minutes), initiate immediate intravenous therapy with labetalol or use oral short-acting nifedipine. 1, 2

First-Line Oral Antihypertensive Agents

The most recent 2025 guidelines establish a clear hierarchy for oral therapy:

Extended-Release Nifedipine (Preferred)

• Once-daily dosing improves adherence, making it the practical first choice 1
• Use long-acting formulation for maintenance therapy
• Reserve short-acting nifedipine for rapid treatment of severe hypertension
• Meta-analysis data shows nifedipine has lower risk of persistent hypertension compared to hydralazine (RR 0.40) and labetalol (RR 0.71) 3
• Achieves treatment success in 84-100% of women 4

Common side effects to monitor: headaches, tachycardia, peripheral edema 1

Labetalol (Alternative or Add-On)

• Use when nifedipine causes intolerable side effects
• Can be combined with nifedipine for uncontrolled BP
• Critical contraindication: reactive airway disease 1
• Requires TID or QID dosing due to accelerated pregnancy metabolism (major disadvantage) 1
• Minimal risks: potential fetal growth restriction, fetal bradycardia, hypoglycemia—but no teratogenicity reported 1

Methyldopa (Third-Line)

• Only medication with long-term infant outcome data 1
• Should NOT be used for urgent BP reduction 2
• Poorly tolerated: peripheral edema, dry mouth, lightheadedness, drowsiness, mood effects 1
• Primarily used in low- and middle-income countries where other agents unavailable 1
• Less effective than β-blockers and calcium channel blockers for preventing severe hypertension 1

Important caveat: Avoid atenolol throughout pregnancy due to fetal growth restriction risk 1

Indications for Intravenous Therapy

Hypertensive Emergency Criteria

Immediate IV treatment is warranted when:

• BP ≥160/110 mmHg lasting >15 minutes 2
• SBP >160 mmHg specifically associated with adverse maternal outcomes (stroke, pulmonary edema) 2

IV Agent Selection

First-line IV options 2:

• Labetalol IV: Currently suggested as first-line
• Oral nifedipine: Can be used for rapid treatment (short-acting formulation)

Critical warning: Do NOT give magnesium sulfate (used for eclampsia prevention) concomitantly with calcium channel blockers—risk of severe hypotension due to synergism 2

Treatment Algorithm by Blood Pressure Level

Non-Severe Hypertension (140-149/90-99 mmHg)

• Non-drug management recommended initially 5
• Consider initiating treatment if gestational hypertension with proteinuria, pre-existing hypertension with superimposed gestational hypertension, or asymptomatic organ damage present 5

Moderate to Severe (≥150/95 mmHg)

• Initiate oral antihypertensive treatment 5
• Start with extended-release nifedipine
• Add or switch to labetalol if needed

Hypertensive Emergency (≥160/110 mmHg >15 min)

• Immediate IV therapy 2
• Labetalol IV or oral short-acting nifedipine
• Monitor for maternal hypotension (occurs in <2% with nifedipine) 4
• Monitor fetal heart rate closely due to potential worsening fetal circulation 6

Postpartum Management

First-line agents postpartum (regardless of breastfeeding status) 1:

• Nifedipine (preferred—once daily)
• Amlodipine (once daily)
• Enalapril (once daily)
• Labetalol (less preferred—requires twice-daily or more frequent dosing and associated with higher readmission risk) 1

Key postpartum consideration: 10% of maternal deaths from hypertensive disorders occur postpartum; close monitoring in early postpartum period is essential 2

Common Pitfalls to Avoid

1. Do not use methyldopa for urgent BP reduction—it is ineffective for this purpose 2
2. Avoid atenolol—associated with fetal growth restriction 1
3. Never combine magnesium sulfate with calcium channel blockers—risk of severe hypotension 2
4. Do not use short-acting nifedipine for maintenance—only for acute severe hypertension 1
5. Monitor for labetalol's accelerated metabolism—may need more frequent dosing than expected 1
6. Watch fetal heart rate when treating severe hypertension—antihypertensive therapy can worsen fetal circulation 6

The evidence strongly supports nifedipine as the most practical first-line agent due to superior adherence with once-daily dosing and comparable or better efficacy versus alternatives, with labetalol reserved for specific situations or combination therapy 1, 3, 4.